Keurig Green Mountain, Inc. fka Green Mountain Coffee Roasters, Inc. Securities Litigation (2011)

According to the Complaint, Keurig Green Mountain, Inc. ("GMCR" or the "Company") and its subsidiaries operate in the specialty coffee and coffee maker businesses. The Company has achieved significant growth in recent years, driven by sales from its popular Keurig single-cup brewing system, which uses "K-Cup" portion packs to brew single servings of coffee and other beverages.

See Case Details »

GlobalSCAPE, Inc. Securities Litigation

According to the law firm press release, the lawsuit alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) Global overstated the reported amounts of accounts receivable as of December 31, 2016, and license revenue for the three months and year ended December 31, 2016, by approximately $403,000 and $396,000, respectively, resulting in the overstatement of the Company's revenues for those periods by the same amounts; (ii) the Company's total current assets and total assets were overstated by $292,000; (iii) the Company's total stockholder equity and total liabilities and stockholders' equity were overstated by $217,000 and $292,000, respectively; (iv) the Company lacked adequate internal controls over financial reporting; and (v) that as a result, Global's publicly disseminated financial statements were materially false and misleading.

See Case Details »

LRR Energy, L.P. Securities Litigation

According to the Complaint, it is alleged the Proposed Acquisition is designed to unlawfully divest LRR Energy unitholders of the Company's valuable assets for grossly inadequate consideration and without fully disclosing all material information concerning the transaction to unitholders.

See Case Details »

Allergan, Inc. Derivative Securities Litigation : Pershing Square Capital Management, L.P.

This action stems from the illicit insider trading and front-running scheme that caused billions of dollars in damages. During the Class Period, Pershing Square Capital Management, L.P., PS Management GP, LLC, William Ackman, PS Fund 1, LLC ("PS Fund 1"), Pershing Square, L.P., Pershing Square II, L.P., Pershing Square GP, LLC , Pershing Square International and Pershing Square Holdings, Ltd. (collectively, "Pershing"), through a funding vehicle named PS Fund 1 purchased over 14 million Allergan shares at prices as low as $117.91 per share for a total cost of approximately $2 billion. Pershing's purchases were based upon inside information concerning Valeant Pharmaceuticals International, Inc.'s ("Valeant") plans to launch a hostile takeover and tender offer for Allergan, and allowed Pershing to reap enormous profits at the expense of Plaintiff and other members of the Class.

See Case Details »

Akari Therapeutics, Plc Securities Litigation

According to the law firm press release, the complaint filed in this class action lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company\'s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company\'s CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; (2) that the Company lacked adequate checks and protections to prevent such behavior; and (3) that, as a result of the foregoing, Defendants\' statements about Akari\'s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

See Case Details »